Completed PHASE2 INTERVENTIONAL 2-arm NCT02611752

A Multiple Dose Opioid Challenge Study

A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder

Sponsor: Braeburn Pharmaceuticals

Conditions Moderate or Severe Opioid Use Disorder

Interventions CAM2038

Updated 7 times since 2017 Last updated: Nov 11, 2019 Started: Oct 31, 2015 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Moderate or Severe Opioid Use Disorder and is currently completed. Braeburn Pharmaceuticals leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Braeburn Pharmaceuticals

Data source: Braeburn Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

A Multiple Dose Opioid Challenge Study

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials